PF-5190457

Investigational

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C29H32N6OS
Molecular Weight	512.669
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

SMILES

CC1=CN2C=C(CC(=O)N3CCC4(CN(C4)[C@@H]5CCC6=C5C=CC(=C6)C7=CC(C)=NC=N7)CC3)N=C2S1

InChI

InChIKey=ZIUDADZJCKGWKR-AREMUKBSSA-N

InChI=1S/C29H32N6OS/c1-19-11-25(31-18-30-19)22-3-5-24-21(12-22)4-6-26(24)35-16-29(17-35)7-9-33(10-8-29)27(36)13-23-15-34-14-20(2)37-28(34)32-23/h3,5,11-12,14-15,18,26H,4,6-10,13,16-17H2,1-2H3/t26-/m1/s1

HIDE SMILES / InChI

Approval Year

Targets

Targets

Primary Target	Pharmacology	Condition	Potency
Ghrelin receptor 15	Inverse Agonist 85		8.36 null [pKi]

Patents

Patents

Show entries

Name

Type

Language

PF-5190457

Code

English

PF-05190457

Preferred Name

English

ETHANONE, 1-(2-((1R)-2,3-DIHYDRO-5-(6-METHYL-4-PYRIMIDINYL)-1H-INDEN-1-YL)-2,7-DIAZASPIRO(3.5)NON-7-YL)-2-(2-METHYLIMIDAZO(2,1-B)THIAZOL-6-YL)-

Systematic Name

English

Showing 1 to 3 of 3 entries

Previous1Next

Show entries

Code System

Code

Type

Description

CAS

1334782-79-4

PRIMARY

DRUG BANK

DB14870

PRIMARY

PUBCHEM

58438464

PRIMARY

MANUFACTURER PRODUCT INFORMATION

PF-05190457

PRIMARY

MedKoo CAT NO.: 522485, CAS NO.: 1334782-79-4Description: PF-5190457 is an orally available, potent and selective ghrelin receptor inverse agonist. PF-5190457 potently increases insulin secretion in glucose-stimulated human islets. PF-5190457 has a superior balance of ghrelin receptor pharmacology and off-target selectivity. On the basis of its promising pharmacological and safety profile, PF-5190457 was advanced to human clinical trials. (last updated: 11/10/2015).

FDA UNII

FF33NL9U5G

PRIMARY

Showing 1 to 5 of 6 entries

Previous1 2Next

ACTIVE MOIETY


					FF33NL9U5G

PF-5190457

METABOLITE LESS ACTIVE (PARENT)


					AU2B9LG483

PF-06870961